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Estimation of cardiac output and pulmonary
vascular resistance by contrast echocardiography
transit time measurement: a prospective pilot
study
Brian G Choi1*, Reza Sanai1, Benjamin Yang1, Heather A Young2, Ramesh Mazhari1, Jonathan S Reiner1
and Jannet F Lewis1

Abstract
Background: Studies with other imaging modalities have demonstrated a relationship between contrast transit and
cardiac output (CO) and pulmonary vascular resistance (PVR). We tested the hypothesis that the transit time during
contrast echocardiography could accurately estimate both CO and PVR compared to right heart catheterization
(RHC).
Methods: 27 patients scheduled for RHC had 2D-echocardiogram immediately prior to RHC. 3 ml of DEFINITY
contrast followed by a 10 ml saline flush was injected, and a multi-cycle echo clip was acquired from the beginning
of injection to opacification of the left ventricle. 2D-echo based calculations of CO and PVR along with the
DEFINITY-based transit time calculations were subsequently correlated with the RHC-determined CO and PVR.
Results: The transit time from full opacification of the right ventricle to full opacification of the left ventricle
inversely correlated with CO (r = −0.61, p < 0.001). The transit time from peak opacification of the right ventricle to
first appearance in the left ventricle moderately correlated with PVR (r = 0.46, p < 0.01). Previously described
echocardiographic methods for the determination of CO (Huntsman method) and PVR (Abbas and Haddad
methods) did not correlate with RHC-determined values (p = 0.20 for CO, p = 0.18 and p = 0.22 for PVR,
respectively). The contrast transit time method demonstrated reliable intra- (p < 0.0001) and inter-observer
correlation (p < 0.001).
Conclusions: We describe a novel method for the quantification of CO and estimation of PVR using contrast
echocardiography transit time. This technique adds to the methodologies used for noninvasive hemodynamic
assessment, but requires further validation to determine overall applicability.
Keywords: Contrast echocardiography, Hemodynamics, Cardiac output, Pulmonary vascular resistance

Background
Invasive hemodynamic assessment by right heart
catheterization (RHC) is a mainstay of evaluation of patients with pulmonary hypertension and congestive heart
failure, [1,2] but this procedure subjects patients to risks
including venous access complications, arrhythmias and,
in rare circumstances, even death [3]. Non-invasive
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hemodynamic assessment has become commonplace,
often supplanting invasive assessment. Several echocardiographic methods have been developed using echocardiography to estimate pulmonary vascular resistance
(PVR) and cardiac output (CO) [4-8]. However, accurate
assessment of right heart pressures and pulmonary vascular resistance, compared to invasive measurements
has proven less reliable. One different approach was
utilized by Galanti et al. [9], who measured transpulmonary transit times of intravenous Albunex in dogs as
an indicator of cardiac output. They noted an excellent
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correlation between the pulmonary transit rate, as measured by the time to first echocardiographic presence in
the left ventricle, with thermodilution cardiac output. This
technique, however, has not been validated in humans.
Ultrasonic contrast agents have been used to improve
image quality for echocardiography, [10] but a potential
role in assessment of PVR and CO has not yet been defined. Investigators using other imaging modalities have
suggested using transit times to assess these measures
[11-13]. In this prospective pilot study, we tested the hypothesis that transit time assessment during contrastenhanced echocardiography could accurately estimate
both PVR and CO compared to the gold-standard of
RHC in patients without evidence of structural right
heart disease.

Methods
Patients

38 consecutive adult patients clinically referred for rightheart catheterization were evaluated for potential inclusion in the study. The exclusion criteria were known or
suspected right-to-left, bi-directional, or transient rightto-left cardiac shunts or pulmonary arteriovenous malformations (AVM), tamponade, previously documented
moderate to severe tricuspid or pulmonic insufficiency,
right ventricular hypokinesis, or prior adverse reaction
to Definity or hypersensitivity to perflutren. The study
was approved by George Washington University institutional review board, and informed, written consent was
obtained from all patients. After consent, 5 patients were
found to not meet enrollment criteria: 4 did not have
right-heart catheterization (including 1 with suspected
tamponade), 1 had right ventricular systolic dysfunction.
6 patients were excluded from analysis secondary to timing errors with contrast injection (i.e., images were not
acquired simultaneously with contrast injection, the onset of intracardiac contrast arrival was not acquired, the
peak opacification in the left ventricle was not acquired).
The remaining 27 patients were included in the final
analysis.
Contrast echo protocol

Immediately prior to RHC, a complete 2D transthoracic
echocardiogram with Doppler using a full platform
echocardiographic instrument (Philips iE33; Andover,
MA) was performed on each patient in the preprocedural holding area) [14]. Prior to the conclusion of
the study, 3 mL diluted perflutren lipid microsphere solution (8.7 mL normal saline plus 1.3 mL of activated Definity, Lantheus Medical Imaging, N. Billerica, MA, USA)
was injected through an 18-Gauge right antecubital intravenous catheter followed by 10 mL normal saline push,
with a multi-cycle echo clip in the apical 4-chamber window started with the beginning of the injection.
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Echocardiographic hemodynamic assessment

PVR was calculated using two methods: (1) the Abbas
et al. method [4] which uses the ratio of peak tricuspid
regurgitant velocity to right ventricular outflow tract timevelocity integral (TVIRVOT), and (2) the Haddad et al.
method [5] which uses the ratio of the systolic pulmonary
artery pressure to heart rate (PASP/HR) × TVIRVOT. The
CO was calculated by the Huntsman et al. method, [8]
which uses heart rate × stroke volume, where stroke volume is calculated as TVILVOT × LVOT cross-sectional
area.
Right heart catheterization

RHC was performed using a Swan-Ganz catheter introduced via femoral, internal jugular or brachial vein approach following standard methods. CO was calculated
using Fick principle with measured oxygen consumption,
and PVR was calculated using the formula: 80 (mean
pulmonary artery pressure – pulmonary capillary wedge
pressure)/CO.
Image analysis

The multi-cycle echo clip of the contrast injection was
evaluated frame-by-frame using IMPAX® Cardiovascular
Review Station version 7.8 (Agfa HealthCare N.V.;
Morstel, Belgium) to identify time to first bubble appearance in the right ventricle (RV1), full opacification of the
right ventricle (RVFull), peak opacification of the right
ventricle (RVPeak), first bubble in the left ventricle
(LV1), full opacification of the left ventricle (LVFull), and
peak opacification of the left ventricle (LVPeak). For example, in a 26-Hertz clip, 520 frames are recorded in
20 seconds, and the clip was played back frame-byframe to determine the frame in which RV1, RVFull,
RVPeak, LV1, LVFull, and LVPeak occur, and then the
frame number would be divided by 26 to determine the
time in seconds. Full opacification was defined as the
moment the contrast has filled the entire ventricle; peak
opacification was defined as the moment that contrast
brightness has subjectively reached its peak within the
ventricle. Representative images are shown in Figure 1.
The measurements were each read twice by two independent readers, with one month between each series of
readings, and all readers were blinded to previous
measurements.
Statistical analysis

The reference standards for CO and PVR were determined by RHC, and were correlated to the established
echo methods for determination of CO [8] and PVR
[4,5] by Pearson’s correlation. CO and PVR were then
correlated to contrast transit time intervals to determine
the interval with best correlation. Once the transit time
intervals that best correlated to CO and PVR were
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Figure 1 Representative apical 4-chamber view images demonstrating (A) left ventricle and right ventricle prior to contrast injection,
(B) full opacification by Definity contrast of the right ventricle, (C) first appearance of contrast in the left ventricle, and (D) full
opacification of the left ventricle.

established, these intervals were re-measured by the
same reader one month later to establish intra-observer
variability and by a second independent reader for interobserver variability as determined by Spearman correlation. Statistical analysis used SAS version 9.3 (Cary,
NC). A p value less than 0.05 was considered statistically
significant.

Results
27 patients were included in this analysis (Table 1). The
average age was 60 ± 13 years, 52 percent were female,
and the most common indication for RHC was for
evaluation of suspected pulmonary hypertension. As calculated by RHC, the mean cardiac output was 6.2 ±
1.4 L/min; cardiac index was 3.1 ± 0.8 L/min/m2. The
mean PVR was 1.8 ± 1.2 Wood units (WU).
CO determined by echo, using the Huntsman method,
was 4.3 ± 1.5 L/min. Correlation of echo CO by Huntsman method and RHC CO by Fick method showed no
significant correlation (r = 0.15, p = 0.20). Echo calculation of PVR, using either the Abbas or the Haddad

Table 1 Clinical characteristics of study patients
Characteristics
Mean Age ± SD

60 ± 12.8 years

Females (%)

52%

Body Surface Area ± SD

1.98 ± 0.21 m2

Indications for RHC
Pulmonary Hypertension

9 (33%)

Dyspnea

8 (30%)

Cardiomyopathy

7 (26%)

Acute Heart Failure

3 (11%)

LV EF (%)

50 ± 16.0

Mean RA pressure (mm Hg)

8±5

Mean PA pressure (mm Hg)

26 ± 10.7

Mean PCWP (mm Hg)

14 ± 7.7

Cardiac Output (L/min)

6.15 ± 1.4

Cardiac Index (L/min/m2)

3.06 ± 0.77

PVR (WU)

1.78 ± 1.15

PVR (WU/m2)

0.88 ± 0.56
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method, showed no significant correlations to PVR determined by RHC (Table 2).
Using echo contrast transit times, CO best correlated
to the time between RVFull and LVFull (r = −0.61, p <
0.001), with shorter transit time correlating to higher
CO (Figure 2). This mean transit time was 3.2 ± 1.2 seconds. From the linear regression analysis, CO =13 – (2 ×
transit time). Intra-observer Spearman correlation was
0.92 (p < 0.0001), and inter-observer Spearman correlation was 0.79 (p < 0.001). The mean intra-observer difference was 0.4 ± 0.3 seconds; the mean inter-observer
difference was 2.1 ± 1.5 seconds.
PVR best correlated to the time between RVPeak and
LV1 (r = 0.46, p < 0.01), with a longer transit time correlating with higher PVR (Figure 3). The mean transit time
was 1.3 ± 0.7 seconds. From the linear regression analysis, PVR = (3.7 × transit time) – 2.9. Intra-observer
Spearman correlation was 0.82 (p < 0.0001), and interobserver Spearman correlation was 0.79 (p < 0.001). The
mean intra-observer difference was 0.4 ± 0.3 seconds;
the mean inter-observer difference was 1.0 ± 0.7 seconds.

Discussion
Our results suggest that the estimation of PVR and CO
using ultrasonic contrast agent transit times during
echocardiography is feasible, accurate and reproducible.
Using our methodology, PVR and CO correlated better
with RHC-derived PVR and CO compared to previously
established methods using echocardiography. Furthermore, our proposed method may be performed on any
PACS system that allows frame-by-frame visualization.
Slow transit from the right to left heart corresponded to
decreased CO and increased PVR. Definity microsphere
particles generally range in size of 1.1-3.3 microns with a
maximum of 20 microns which facilitate its passage
across the pulmonary vasculature (pulmonary capillary
diameter averages 7 microns) into left heart chambers
[15]. For this reason, we speculate that the reason PVR

Figure 2 Cardiac output by right heart catheterization
correlated to Definity contrast transit time between full
opacification of the right ventricle and full opacification of the
left ventricle.

correlates with transit time is that a decrease in average
pulmonary capillary diameter would slow transit; therefore, from peak contrast enhancement in the right ventricle to its first appearance in the left heart may
correlate to PVR. The time the contrast takes to fully
opacify the right ventricle to full opacification of the left
ventricle would be more rapid with high cardiac output,
which is what we found in the current study. In addition,
our PVR method is derived independently of the need
for the estimation of the pulmonary artery systolic pressure, which is not possible in cases where the tricuspid
regurgitant jet is inadequate.
Previously established methods for estimation of PVR
[4,5] did not correlate with results found by cardiac
catheterization. Notably, other studies also found poor
correlation with these methods, especially for those patients with high PVR [16,17], underscoring the need for
alternative methods of non-invasive determination of
PVR that may more reproducible. A limitation of the

Table 2 Correlation of cardiac output (CO) and
pulmonary vascular resistance (PVR) as determined by
right heart catheterization (RHC) and established
methods of echocardiographic determination [4,5,8]
Method of
calculation

RHC
measured
Mean ± SD

ECHO
calculated
Mean ± SD

Correlation

P value

CO-Huntsman
(L/min)

6.17 ± 1.37

4.34 ± 1.47

0.152

0.204

PVR-Abbas
(TRV/RVOT × 10)
Wood Units

1.44 ± 1.07

1.59 ± 0.71

0.182

0.181

PVR-Haddad
(SPAP/(RVOT
VTI×HR))
Wood Units/m2

0.72 ± 0.52

0.26 ± 0.15

0.158

0.216

Figure 3 Pulmonary vascular resistance by right heart
catheterization correlated to Definity contrast transit time
between peak opacification of the right ventricle and first
appearance in the left ventricle.
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Abbas method [4] is its reliance on the velocity time integral of the right ventricular outflow tract, a measurement that is not easily measurable in the patient with
significant pulmonary hypertension [18]. Furthermore,
this method requires assessment of the tricuspid regurgitant jet velocity, a measure that may not be assessed for
every patient if the jet is inadequate [19]. Similarly, the
Haddad method [5] is also dependent on a reliably assessable transtricuspid regurgitant jet and right ventricular outflow tract velocity time integral. Our proposed
method is independent of the need to assess these measures and may explain why our proposed method correlated better with catheterization-derived values.
Other investigators have pointed out the limitations of
the Huntsman method [8] for determination of cardiac
output by ultrasound: accurate velocity measurement requires good alignment between Doppler beam and blood
flow [20] and reliable measurement of cross-sectional
area for flow [21]. With the increased scrutiny of the
echocardiographic measurement of left ventricular outflow tract dimensions, it is now well understood that the
cross-section of the left ventricular outflow tract is not
circular and relying on the diameter alone to calculate
the cross-sectional area may lead the additional inaccuracy [22]. Our method is independent of these measurements and may explain the better correlation with CO.
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events in 1,060 patients, but the Definity-related adverse
event rate was 3.5%, primarily headache, nausea, back
pain and tremor [24].

Conclusions
This pilot study demonstrates that estimation of PVR
and CO by measurement of ultrasonic contrast times
may be superior to previously established echocardiographic methods. Further validation of this novel
method may obviate the need for invasive assessment.
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In an effort to reduce confounding sources of variability,
this pilot study was limited to patients without evidence
of structural right heart disease. We presumed that severe tricuspid regurgitation, severe pulmonary regurgitation, and right ventricular systolic dysfunction would
prolong transit times and PVR and CO would not correlate in these circumstances. In addition, 6 patients
were excluded from analysis because of timing errors
with contrast injection. Our sonographers were not previously accustomed to timing image acquisition with the
moment of contrast injection, and our protocol required
a higher level of coordination between the sonographer
and the person injecting the contrast agent. We suspect
that this coordination issue may be a reason that our derived measures that correlated best with PVR and CO
are measures that are independent of the moment of initial injection. PVR requires timing from the moment of
peak RV opacification and CO requires timing from the
moment of RV full opacification; both of these moments
are independent of the time of initial injection.
Definity contrast is not without safety limitations. The
rates of serious adverse reactions associated with DEFINITY use are extremely rare as was demonstrated by
retrospective cohort study of 42,408 patients, and 1 in
10,000 patients experienced an allergic reaction [23]. A
prospective multicenter trial found no serious adverse
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